 Launched first product, the Nu.Q Vet Cancer Screening Test and recorded first revenue from sales of a commercial product Engaged Diagnostic Oncology CRO LLC to conduct U.S. regulatory clinical trial for Non-Hodgkins Lymphoma Expanded research program for the use of Nu.Q technology in NETosis COVID-19 and sepsis Strengthened intellectual property portfolio Purchased and opened first production facility Strongest-ever cash position following a public offering in February 2021 AUSTIN, Texas, March 22, 2021 PRNewswire -- VolitionRx Limited NYSE AMERICAN: VNRX Volition today announced financial results and a business update for the full fiscal year ended December 31, 2020. Volition management will host a conference call tomorrow, March 23 at 8:00 a.m. 